MP14-18 NEOADJUVANT COMBINATION OF PAZOPANIB OR AXITINIB AND PD-1-ACTIVATED DC-CIK CELLS IMMUNOTHERAPY MAY FACILITATE SURGERY IN PATIENTS WITH RENAL CELL CARCINOMA

Abstract

You have accessJournal of UrologyKidney Cancer: Advanced (including Drug Therapy) I (MP14)1 Sep 2021MP14-18 NEOADJUVANT COMBINATION OF PAZOPANIB OR AXITINIB AND PD-1-ACTIVATED DC-CIK CELLS IMMUNOTHERAPY MAY FACILITATE SURGERY IN PATIENTS WITH RENAL CELL CARCINOMA Longbin Xiong, Zeshen Wu, Pei Dong, Huiming Liu, Kang Ning, Yulu Peng, Chunping Yu, Ya Ding, Desheng Weng, Jianchuan Xia, Lijuan Jiang, Shengjie Guo, Hui Han, Fangjian Zhou, and Zhiling Zhang Longbin XiongLongbin Xiong More articles by this author , Zeshen WuZeshen Wu More articles by this author , Pei DongPei Dong More articles by this author , Huiming LiuHuiming Liu More articles by this author , Kang NingKang Ning More articles by this author , Yulu PengYulu Peng More articles by this author , Chunping YuChunping Yu More articles by this author , Ya DingYa Ding More articles by this author , Desheng WengDesheng Weng More articles by this author , Jianchuan XiaJianchuan Xia More articles by this author , Lijuan JiangLijuan Jiang More articles by this author , Shengjie GuoShengjie Guo More articles by this author , Hui HanHui Han More articles by this author , Fangjian ZhouFangjian Zhou More articles by this author , and Zhiling ZhangZhiling Zhang More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001995.18AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: To evaluate the efficacy and safety of neoadjuvant combination of pazopanib or axitinib and PD-1-activated dendritic cell-cytokine-induced killer (PD-1/DC-CIK) cells immunotherapy in locally advanced or highly complicated renal cell carcinoma (RCC). METHODS: Data from 16 RCC patients received neoadjuvant pazopanib (Group P, N=9) or axitinib (Group A, N=7) plus PD-1/DC-CIK cells immunotherapy were reviewed retrospectively. Nine patients that were potential candidates for radical/cytoreductive nephrectomy (RN/CN) had locally advanced tumor and five patients with partial nephrectomy (PN) absolute indications had highly complicated tumor. The efficacy outcomes were based on the changes of volume of primary tumor, lymph nodes, and tumor thrombus in 13 patients with complete CT imaging. Besides, the treatment-related toxicities and surgical complications were also reported. RESULTS: With a median of 2.1 months treatment, the overall volume of the tumors decreased by a median of 42.30% (IQR:19.37%-66.78%). Specifically, the median reduction of tumor volume was 88.77 cm3 and 15.50 cm3 in group P and group A, respectively (p=0.014). However, patients in Group P were more likely to experience grade 3 or 4 treatment-related adverse events (AEs) than those in Group A (44.4% vs. 0). Finally, all patients could receive appropriate surgery after neoadjuvant therapy assessed by surgeon, and 10 patients accepted surgery, including 5 PN, 4 RN/CN and 1 lymph node dissection. One had Clavien grade Ⅳ acute renal failure and 1 had grade Ⅱ lymphatic leakage. CONCLUSIONS: Neoadjuvant combination of pazopanib or axitinib and PD-1/DC-CIK cells immunotherapy was well-tolerated and could effectively reduce the volume of tumors in locally advanced or highly complicated RCC patients. Source of Funding: No © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e260-e261 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Longbin Xiong More articles by this author Zeshen Wu More articles by this author Pei Dong More articles by this author Huiming Liu More articles by this author Kang Ning More articles by this author Yulu Peng More articles by this author Chunping Yu More articles by this author Ya Ding More articles by this author Desheng Weng More articles by this author Jianchuan Xia More articles by this author Lijuan Jiang More articles by this author Shengjie Guo More articles by this author Hui Han More articles by this author Fangjian Zhou More articles by this author Zhiling Zhang More articles by this author Expand All Advertisement Loading ...